Pregnancy drug given to 300,000 women linked to 30 per cent higher cancer risk
Health Secretary Wes Streeting may start an enhanced screening programme after a pregnancy drug given to hundreds of thousands of women was linked to cancer.
The minister was responding to an ITV News investigation into links between cancer cases and the drug Stilbestrol, also known as Diethylstilbestrol (DES). They revealed the drug was still being prescribed to mothers nearly a decade after being supposedly banned. It was prescribed to an estimated 300,000 women from 1939 until the late 1970s to prevent miscarriage and stop breast milk production.
Research suggests women who took DES may have a 30% higher risk of breast cancer. If the drug was taken while pregnant, the harm can be passed down the generations with daughters exposed in the womb at increased risk of clear cell cancer of the cervix and vagina and reproductive abnormalities.
The health secretary told ITV News Social Affairs correspondent Sarah Corker: 'There is more to do to look at this historic injustice.'
On calls for enhanced cancer screening for mothers exposed to DES, the Health Secretary responded: 'I am certainly open to looking at that, that is one of many things that the government is looking at, in light of ITV's investigation.'
DES has been described as a 'hidden thalidomide' - with the harm passed down 'generations'. An ITV News investigation has led to more than 100 women fearing their health has been damaged because of DES.
Some who have come forward are suffering from "barbaric" pain and rare cancers - but it is feared there could be thousands more.
Other countries around the world, such as the United States, banned the drug in the 1970s as scientific studies linked the use of DES with breast, cervical and vaginal cancers.
But in the UK, health authorities failed to do the same.
The UK government claimed a letter was sent to all doctors in 1973 telling them to stop using DES for pre-menopausal women, but ITV News said they had found dozens of women who say they were given it after that date, some as late as 1980.
They also searched through hundreds of pages of public health records at the British Library and National Archives and there is no evidence of the 1973 letter.
Susan Miller, 72, from London, believes she was given the drug in 1975 after the birth of her daughter to stop her breast milk – two years after the government said it was supposed to have been stopped.
She questioned doctors about the drug's side effects whilst on the maternity ward but told ITV News her concerns were dismissed. She said: 'I was lied to. It's absolutely disgusting. I should have never been given the drug. It's ruined so many people's lives.
'It's not just me; it's other women as well. They are walking round with time bombs in their breasts, because they even don't know, so they can't even get checked.'
The mother-of-one believes the effect on her health has been devastating. She's survived blood cancer but is now being treated for an aggressive form of breast cancer.
In response to the ITV News investigation, a Department of Health and Social Care spokesperson said: 'Our sympathies are with anyone harmed by the historic use of Diethylstilboestrol (DES).
'The Secretary of State has been clear he will look seriously at these allegations, and the government will continue to consider enhanced screening for those impacted by the use of this drug.'
Dr Alison Cave, MHRA Chief Safety Officer, told ITV: 'We express our sympathies with those harmed by the historic use of Diethylstilboestrol (DES).
'We are continuing to invest significant resource to locate historical documentation relating to regulatory decisions on DES made in the 1970s, over 50 years ago. Due to the age and format of the records, this is a complex and time-consuming process.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Herald Scotland
28 minutes ago
- The Herald Scotland
Mounjaro prices double as weight loss jab popularity soars
A Lilly spokesperson said: 'Following a review, Lilly will increase the UK list price for Mounjaro (tirzepatide) from 1 September to address pricing inconsistencies compared to other developed countries, including in Europe. We have reached an agreement with the NHS to ensure continued supply and patient access." The statement continues: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access. The UK was one of the first countries where Lilly launched Mounjaro, and our priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability." More than 1.5 million people in the UK are believed to be using weight-loss medication each month, with most buying the jabs from private pharmacies. Mounjaro users report surprising side effect - pharmacists share their tips — Bucks Free Press (@bucksfreepress) August 8, 2025 This comes as the Government has joined forces with Eli Lilly in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Recommended reading: Mounjaro warning as pens ruined by heatwave temperatures This comes as users are risking having to throw away perfectly good Mounjaro pens as they have overheated in the recent heatwave. Improper storage of Ozempic, Wegovy and Mounjaro during a heatwave could destroy the active ingredient in these jabs, potentially wiping out their effects entirely, even if the medication looks completely normal. 'We recommend treating your weight-loss pen the same way you'd treat insulin or any critical medication,' says Danielle Brightman, Clinical Director at Numan. 'When in doubt, don't risk it. Speak to a healthcare professional and arrange a replacement.' 8 tips to protect Mounjaro and other weight-loss injections during hot weather Use a medical-grade cool bag. Transport your pen in a proper, insulated container designed for sensitive medications. Don't use improvised ice packs that might freeze the pen by accident. Never leave your pen in hot places. Even 10 minutes in a parked car or on a sunny kitchen counter could expose it to damaging heat if out of its delivery packaging or unrefrigerated. Always check the environment before setting it down. Store below 30°C once in use. Once opened and if not refrigerated, keep your pen in a shaded, ventilated area, away from heat sources, windows, and radiators. If you live in a flat or home without air conditioning, keep the pen in a bedroom or hallway that doesn't heat up from direct sun. Avoid storing near exterior walls if the property retains heat. Follow the usage timeline carefully. The storage instructions between medications. Wegovy after first use can last 6 weeks below 30 degrees then needs to be disposed of, whereas Mounjaro has a shorter time of 30 days below 30 degrees before needing to be disposed of. Stick to that timeframe, and if you're unsure whether it's still safe, consult your provider. Use a fridge thermometer at home. Fridge temperatures can fluctuate, especially in older models or over-packed shelves. A simple digital fridge thermometer can help ensure your pen is always stored between 2–8°C before first use. Planning to travel? Use airline-friendly cooling cases. If you're flying or taking long journeys, consider TSA-approved insulated medication pouches with cooling gel packs. Always store the pen in carry-on luggage, not checked baggage, as cargo holds can get hot or cold. Set storage reminders on your phone. If you're prone to forgetting where you left your pen, set daily reminders to check if it's stored properly, especially during heatwaves or while travelling. Don't store near appliances or steam sources. Keep pens away from kettles, toasters, ovens, dishwashers, and anywhere that might experience sudden heat or humidity, especially in small kitchens or shared spaces. Injections like Ozempic, Wegovy, and Mounjaro are now widely used across the UK for appetite control and sustainable weight management. But despite their growing popularity and increasing availability now through the NHS, most patients don't realise the strict temperature guidelines that must be followed to keep these drugs effective. 'We speak to patients every day who are using GLP-1s for the first time,' says Danielle. 'With temperatures set to soar again this summer, it's crucial we raise awareness about safe medication storage. Heat damage isn't always obvious, but it can have a huge impact on effectiveness and safety."
The Independent
an hour ago
- The Independent
This Morning star reveals she had a miscarriage while presenting live on air
You can contact the Miscarriage Association helpline on 01924 200799 or email the charity at info@ The helpline is open from 9am to 4pm Monday to Friday. For more information, help and support regarding pregnancy loss, you can contact Tommy's on 0800 0147 800. This Morning star Dr Zoe Williams has revealed she suffered a miscarriage live on air, while presenting the show. Appearing on Thursday's (14 August) episode of the ITV show, the 45-year-old spoke about her loss for the first time, which happened following the birth of her four-year-old boy. Speaking during a segment which featured Olympian Rebecca Adlington discussing her own experience with premature pregnancy losses, Dr Williams said she chose to share her story in an effort for women to 'talk more and be more open'. She revealed she had suffered two miscarriages, with her second happening while she was sat on the This Morning sofa, saying: 'I say that because you will know people going through this. 'People often get on with it, they go to work, no one knows.'
Telegraph
an hour ago
- Telegraph
Waiting list rises after row over NHS figures
The NHS waiting list has risen again as it is 'struggling to keep pace with demand'. The backlog rose by 10,000 to 7.37 million as of the end of June, compared with the previous month, driven by an increase in the number of patients being referred for appointments. It comes as experts revealed the NHS waiting list data was 'misleading' because it did not publish the number of 'unreported removals' – where patients who no longer need an appointment because of a variety of reasons have been deleted from the list. The Nuffield Trust think tank's analysis revealed as many as 245,000 people per month were being taken off the waiting list through these 'validation processes', and highlighted that fewer patients were being treated than added to the backlog. The Government said this only accounted for 15 per cent of the fall in the backlog since it took charge last July, with the waiting list down from 7.6 million on last July. The NHS said it had treated more than 100,000 people in June, up 2 per cent on the year before, but 141,000 patients joined the waiting list. The number of people waiting the longest also fell, with just 1,100 waiting more than 18 months. Dr Becks Fisher, director of research and policy at the Nuffield Trust, said the figures remain 'stubbornly high at 7.37 million and the NHS is struggling to keep pace with demand'. 'But the reported numbers on the planned treatment waiting list only show part of the picture,' she said. 'Our new analysis shows that waiting list reductions in previous months are not wholly due to increases in appointments being delivered. In fact, the NHS is still treating fewer patients than are being referred.' She added: 'We should be under no illusions that despite delivering more appointments, the NHS is still not meeting patient demand. 'The Health Secretary has praised 'record investment and fundamental NHS reform' as the reasons behind reductions in the waiting list earlier this year, but there are lingering background causes that go unmentioned.' Wes Streeting, the Health Secretary, said the Government had gone beyond its promise to deliver two million more appointments. 'One year on, we have delivered almost an extra five million appointments. As a result, today's figures show that, despite record numbers of people coming forward for treatment, we are cutting waiting times, with the lowest number of patients waiting more than 18 weeks for treatment in three years,' he said. Separate figures published by the NHS showed that 11,000 more appointments and procedures went ahead during junior – now called resident – doctor strikes last month, compared to last July's five-day walkout. Mr Streeting will continue discussions with the British Medical Association throughout the summer in a bid to avert further industrial action. The Health Secretary said the figures show the NHS 'was more resilient against last month's strike action than ever before'. 'We are getting on with the job of delivering progress in the face of strike action, and we will continue to put patients first,' he said. Professor Meghana Pandit, NHS national medical director, said: 'It is very welcome news that the Resident Doctors Committee has returned to talks – and we hope this leads to a resolution that avoids further disruption for patients.' Meanwhile, data on A&E wait times shows 76.4 per cent of patients were seen within four hours last month, up from 75.5 per cent in June. The number of patients waiting 12 hours for a hospital bed fell to 35,467 from 38,683 a month earlier. Despite this reduction, Dr Nick Murch, president of the Society for Acute Medicine, described the 12-hour wait figure as 'unacceptable'. He said: 'Clinicians across the UK are reporting this week as one of the worst they have experienced, with no sign of the brief respite seen in the immediate aftermath of recent strike action, yet there remains no tangible and immediate action to address urgent workforce and capacity issues. 'Sadly, instead, recent commentary and reporting suggests a growing reliance on selective or misleading interpretations of NHS data, as highlighted this week in analysis by the Nuffield Trust, which calls into question claims the NHS is being turned around.' Mr Tim Mitchell, president of the Royal College of Surgeons of England, said the waiting list rise was 'likely down to seasonal ebbs and flows'. 'However, as analysis published this week shows, the drop in waiting list numbers we've seen prior to this month doesn't necessarily mean more patients are being treated,' he said. 'The Government should be honest that a significant part of recent reductions reflects validation exercises rather than increased surgical activity. 'Ultimately, only further investment to expand the NHS' capacity will deliver substantial reductions in waiting times,' he added. Helen Morgan MP, the Liberal Democrat health spokesman, said: 'This Government is doing no better than treading water on getting the waiting list down. 'These figures will add salt to the wounds of [Wednesday's] news that Labour appear to be cooking the books – boasting of treating phantom patients who have in fact died, moved or desperately had to seek treatment elsewhere.'
